Cogent Biosciences, Inc. (COGT) stock
COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 2/30
$27.44−1.12 (-3.92%)
Close on Nov 16, 2026Market cap $4.76BP/E –Yield –
Cogent Biosciences ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Cogent Biosciences's ebitda for the twelve months ending Jun 30, 2026 was -$386.42M. For fiscal 2025 it was -$330.76M. The highest annual figure on record is -$24.98M in fiscal 2017.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$330.76M | – |
| FY2024 | Dec 31, 2024 | -$273.44M | – |
| FY2023 | Dec 31, 2023 | -$205.83M | – |
| FY2022 | Dec 31, 2022 | -$147.04M | – |
| FY2021 | Dec 31, 2021 | -$75.40M | – |
| FY2020 | Dec 31, 2020 | -$81.48M | – |
| FY2019 | Dec 31, 2019 | -$30.89M | – |
| FY2018 | Dec 31, 2018 | -$34.68M | – |
| FY2017 | Dec 31, 2017 | -$24.98M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$101.90M | – |
| Q1 FY2026 | Mar 31, 2026 | -$102.98M | – |
| Q4 FY2025 | Dec 31, 2025 | -$98.83M | – |
| Q3 FY2025 | Sep 30, 2025 | -$82.71M | – |
| Q2 FY2025 | Jun 30, 2025 | -$74.93M | – |
| Q1 FY2025 | Mar 31, 2025 | -$74.29M | – |
| Q4 FY2024 | Dec 31, 2024 | -$73.06M | – |
| Q3 FY2024 | Sep 30, 2024 | -$74.79M | – |
| Q2 FY2024 | Jun 30, 2024 | -$63.78M | – |
| Q1 FY2024 | Mar 31, 2024 | -$61.81M | – |
| Q4 FY2023 | Dec 31, 2023 | -$57.60M | – |
| Q3 FY2023 | Sep 30, 2023 | -$59.00M | – |
| Q2 FY2023 | Jun 30, 2023 | -$46.52M | – |
| Q1 FY2023 | Mar 31, 2023 | -$42.71M | – |
| Q4 FY2022 | Dec 31, 2022 | -$43.37M | – |
| Q3 FY2022 | Sep 30, 2022 | -$36.57M | – |
| Q2 FY2022 | Jun 30, 2022 | -$35.76M | – |
| Q1 FY2022 | Mar 31, 2022 | -$31.35M | – |
| Q4 FY2021 | Dec 31, 2021 | -$25.57M | – |
| Q3 FY2021 | Sep 30, 2021 | -$19.77M | – |
| Q2 FY2021 | Jun 30, 2021 | -$17.28M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.78M | – |
| Q4 FY2020 | Dec 31, 2020 | -$11.44M | -547.9% |
| Q3 FY2020 | Sep 30, 2020 | -$57.08M | – |
| Q2 FY2020 | Jun 30, 2020 | -$7.12M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.85M | – |
| Q4 FY2019 | Dec 31, 2019 | $2.55M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.72M | – |
| Q2 FY2019 | Jun 30, 2019 | -$10.21M | – |
| Q1 FY2019 | Mar 31, 2019 | -$11.51M | – |
| Q4 FY2018 | Dec 31, 2018 | -$8.65M | – |
| Q3 FY2018 | Sep 30, 2018 | -$10.25M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.11M | – |
| Q1 FY2018 | Mar 31, 2018 | -$6.67M | – |
| Q4 FY2017 | Dec 31, 2017 | -$6.57M | – |
| Q3 FY2017 | Sep 30, 2017 | -$6.87M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.75M | – |
| Q1 FY2017 | Mar 31, 2017 | -$5.79M | – |
See a number that looks wrong?